Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction... | May 5, 2023